Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
Mohamad Adham Salkeni,1 Wajeeha Rizvi,2 Kyaw Hein,3 Gerald M Higa4 1Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; 2Department of Internal Medicine, West Virginia University, Morgantown, WV, USA; 3Department of Business, Lamar...
Guardado en:
Autores principales: | Salkeni MA, Rizvi W, Hein K, Higa GM |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/46bae7ee4c0f4a189823d454f63a5b4d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review
por: Linehan AS, et al.
Publicado: (2021) -
Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
por: Jagosky M, et al.
Publicado: (2021) -
Impact of HER2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinoma
por: Kustic,Domagoj, et al.
Publicado: (2019) -
Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature
por: Belal Firwana, et al.
Publicado: (2012) -
Características clínicas y pronóstico de pacientes con cáncer de mama HER2 positivo avanzado, en la era antes y después de terapias anti-HER2
por: SÁNCHEZ,CESAR, et al.
Publicado: (2018)